Page 35 of 38: studies 341 to 350 of 375, newest first. Back to the CBD overview
March 1, 2017 Linda A. Parker
Cannabinoids and the Brain introduces an informed general audience to the scientific discovery of the endocannabinoid system and recent preclinical research that explains its importance in brain functioning. The endocannabinoids, anandamide and 2-AG, act on the same cannabinoid receptors, that are activated by the primary psychoactive compound found in marijuana, Δ9-tetrahydrocannabinol (THC)....
Cannabinoids and the Brain March 1, 2017 Linda A. Parker
Marijuana is often used for relaxation, therefore, it is not surprising that the endocannabinoid system is critically involved in the regulation of emotion, anxiety and mood. In preclinical animal models, THC and other CB1 agonists produce a biphasic effect on anxiety, with low doses reducing anxiety (by blocking the release of the excitatory neurotransmitter glutamate) and high doses promoting...
Cannabinoids and the Brain March 1, 2017 Linda A. Parker
Global activation of CB1 receptors produces actions on hippocampal neurons, which results in interference with short tem memory and consolidation of memories that are currently being processed. However, such CB1 receptor activation does not impair recall of previously established memories. Evidence suggests that the acute effects of cannabis on memory depend in part on the type of cannabis that...
Journal of Clinical Psychopharmacology December 2016 Martin A Katzman, Melissa Furtado, Leena Anand
Prevalence of psychiatric disorders continues to rise globally, yet remission rates and patient outcome remain less than ideal. As a result, novel treatment approaches for these disorders are necessary to decrease societal economic burden, as well as increase individual functioning. The recent discovery of the endocannabinoid system has provided an outlet for further research into its role in...
World Psychiatry September 22, 2016 Robin Murray, Harriet Quigley, Diego Quattrone et al. 319 citations
Epidemiological evidence demonstrates that cannabis use is associated with an increased risk of psychotic outcomes, and confirms a dose-response relationship between the level of use and the risk of later psychosis. High-potency cannabis and synthetic cannabinoids carry the greatest risk. Experimental administration of tetrahydrocannabinol, the active ingredient of cannabis, induces transient...
Biological Psychiatry April 1, 2016 Samantha J Broyd, Hendrika H Van Hell, Camilla Beale et al.
Cannabis use has been associated with impaired cognition during acute intoxication as well as in the unintoxicated state in long-term users. However, the evidence has been mixed and contested, and no systematic reviews of the literature on neuropsychological task-based measures of cognition have been conducted in an attempt to synthesize the findings. We systematically review the empirical...
Translational Psychiatry February 16, 2016 C J A Morgan, Tom P. Freeman, J Powell et al.
Smoking cannabis daily doubles an individual's risk of developing a psychotic disorder, yet indicators of specific vulnerability have proved largely elusive. Genetic variation is one potential risk modifier. Single-nucleotide polymorphisms in the AKT1 and catechol-O-methyltransferase (COMT) genes have been implicated in the interaction between cannabis, psychosis and cognition, but no studies...
Translational Psychiatry January 12, 2016 Murat Yücel, Valentina Lorenzetti, Chao Suo et al.
Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant ethical issues for health-care providers seeking evidence-based recommendations. We investigated whether heavy cannabis use is associated with persistent harms to the hippocampus, if exposure to cannabidiol offers protection, and whether recovery occurs with abstinence. To do this, we...
Cochrane Database of Systematic Reviews October 14, 2014 Benjamin C McLoughlin, Jonathan A Pushpa-Rajah, Donna Gillies et al.
Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations. Many people with schizophrenia smoke cannabis, and it is unclear why a large proportion do so and if the effects are harmful or beneficial. It is also unclear what the best method is to allow people with schizophrenia to alter their cannabis intake. To assess the effects of specific psychological treatments for...
Neuroscience & Biobehavioral Reviews May 1, 2013 Zoran Vukadinovic, Merrill S Herman, Ivana Rosenzweig
The role of cannabis in the etiology of schizophrenia has been documented as possibly the strongest environmental risk factor. However, the pathomechanism whereby cannabis use increases this risk has not yet been identified. We argue that this pathomechanism may involve direct effects of exogenous cannabinoids on T-type calcium channels in the thalamus. These channels are crucial for...